Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TYRA

TYRA - Tyra Biosciences, Inc. Stock Price, Fair Value and News

$21.65+0.73 (+3.49%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

TYRA Price Action

Last 7 days

-1.7%

Last 30 days

40.3%

Last 90 days

78.3%

Trailing 12 Months

41.9%

TYRA RSI Chart

TYRA Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-10.35

Price/Sales (Trailing)

76.13

Price/Free Cashflow

-12.67

TYRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TYRA Fundamentals

TYRA Revenue

Revenue (TTM)

15.2M

Rev. Growth (Yr)

-32.96%

Rev. Growth (Qtr)

-8.29%

TYRA Earnings

Earnings (TTM)

-111.7M

Earnings Growth (Yr)

-24.37%

Earnings Growth (Qtr)

-6.3%

TYRA Profitability

Return on Equity

-39.81%

Return on Assets

-37%

Free Cashflow Yield

-7.89%

TYRA Investor Care

Shares Dilution (1Y)

5.47%

Diluted EPS (TTM)

-1.87

TYRA Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025016.9M15.2M0
202412.5M14.6M16.4M17.7M
202300010.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Tyra Biosciences, Inc.

TYRA
Tyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÃ…P, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
 CEO
 WEBSITEtyra.bio
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES38

Tyra Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Tyra Biosciences, Inc.? What does TYRA stand for in stocks?

TYRA is the stock ticker symbol of Tyra Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tyra Biosciences, Inc. (TYRA)?

As of Wed Dec 03 2025, market cap of Tyra Biosciences, Inc. is 1.16 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TYRA stock?

You can check TYRA's fair value in chart for subscribers.

Is Tyra Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether TYRA is over valued or under valued. Whether Tyra Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Tyra Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TYRA.

What is Tyra Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, TYRA's PE ratio (Price to Earnings) is -10.35 and Price to Sales (PS) ratio is 76.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TYRA PE ratio will change depending on the future growth rate expectations of investors.